Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
401.1 ^USD	+0.23%		+0.85%	-1.43%

May. 03	S&P 500 Posts Weekly Gain as Weaker-Than-Expected April Jobs Report Boosts Hopes for FOMC Rate Cut	MT
Apr. 26	Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants	MT

TreeFrog Therapeutics SAS announced that it expects to receive $25 million in funding from Vertex Pharmaceuticals Incorporated

April 22, 2024

TreeFrog Therapeutics SAS announced that it will entered into a purchase agreement for gross proceeds of $25 million on April 23, 2024. The transaction include the participation from new investor Vertex Pharmaceuticals Incorporated. The company will issue common shares in the transaction.

Latest news about Vertex Pharmaceuticals Incorporated

S&P 500 Posts Weekly Gain as Weaker-Than-Expected April Jobs Report Boosts Hopes for FOMC Rate Cut	May. 03	MT
Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants	Apr. 26	MT
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older	Apr. 26	CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	Apr. 25	MT
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics	Apr. 23	DJ
TreeFrog Therapeutics SAS announced that it expects to receive $25 million in funding from Vertex Pharmaceuticals Incorporated	Apr. 22	CI
Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain	Apr. 18	MT
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating	Apr. 17	MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445	Apr. 17	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Wall Street rebounds on softer inflation data, eyes on earnings	Apr. 11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
Nasdaq set for higher open as fresh inflation data allays rate jitters	Apr. 11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Top Premarket Gainers	Apr. 11	MT
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say	Apr. 11	MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line	Apr. 11	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST

More Strategies

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

401.1 USD

Average target price

460.2 USD

Spread / Average Target

+14.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B
LEGEND BIOTECH CORPORATION	-24.53%	8.36B

Bio Therapeutic Drugs